Skip to main content
Premium Trial:

Request an Annual Quote

Place All Bets Now

David Pendlebury, an analyst with Thomson Reuters, has made a list of who he says is likely to win the Nobel prize. To make those predictions, Pendlebury drew on information from Thomson Reuters' Web of Knowledge. "We looked first at citation counts and at number of high-impact papers, but then also at discoveries or themes that might be considered worthy of special recognition by the Nobel Committee," Pendlebury says. On his list for the physiology or medicine award are Joseph Vacanti at Massachusetts General Hospital and MIT's Robert Langer for their work in regenerative medicine and Sloan-Kettering's Charles Sawyers, Granite Biopharma's Nicholas Lydon, and Brian Druker at Oregon Health and Science University for their development of imatinib and dasatinib to treat chronic myeloid leukemia.

"The Thomson Reuters list of predicted laureates certainly reads like a who's who of the relevant disciplines, but when it comes time for the Swedes to make their announcements next month, it's anyone's guess whose name will come up," adds John Matson at Scientific American's Observations blog. The medicine prize is due to be announced October 3 and the chemistry prize on October 5.

Paul Bracher from the blog ChemBark tells ScienceInsider that he is planning to live-blog the chemistry announcement. "This is the Oscars for nerds," he says. And he has his own set of predictions here.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.